−0.04 INR
−6.55 M INR
2.35 M INR
About TRANSGENE BIOTEK LTD.
Sector
Industry
CEO
K. Koteswara Rao
Website
Headquarters
Hyderabad
Founded
1991
ISIN
INE773D01018
FIGI
BBG000D19798
Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. It involves in the production and oral formulation of different proteins using TrabiORAL technology. The firm's products portfolio includes TrabiDHA, Tacrolimus, and Orlistat. The company was founded by K. Koteswara Rao in 1991 and is headquartered in Hyderabad, India.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TRABI is 6.94 INR — it has decreased by −6.34% in the past 24 hours. Watch TRANSGENE BIOTEK LTD. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange TRANSGENE BIOTEK LTD. stocks are traded under the ticker TRABI.
TRABI stock has fallen by −5.58% compared to the previous week, the month change is a 5.15% rise, over the last year TRANSGENE BIOTEK LTD. has showed a −37.42% decrease.
TRABI reached its all-time high on Jan 25, 2006 with the price of 322.50 INR, and its all-time low was 1.55 INR and was reached on Jun 6, 2016. View more price dynamics on TRABI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TRABI stock is 13.94% volatile and has beta coefficient of 0.02. Track TRANSGENE BIOTEK LTD. stock price on the chart and check out the list of the most volatile stocks — is TRANSGENE BIOTEK LTD. there?
Today TRANSGENE BIOTEK LTD. has the market capitalization of 487.36 M, it has decreased by −5.87% over the last week.
Yes, you can track TRANSGENE BIOTEK LTD. financials in yearly and quarterly reports right on TradingView.
TRABI net income for the last quarter is −734.00 K INR, while the quarter before that showed 1.99 M INR of net income which accounts for −136.81% change. Track more TRANSGENE BIOTEK LTD. financial stats to get the full picture.
No, TRABI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRANSGENE BIOTEK LTD. EBITDA is −8.64 M INR, and current EBITDA margin is −262.58%. See more stats in TRANSGENE BIOTEK LTD. financial statements.
Like other stocks, TRABI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRANSGENE BIOTEK LTD. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRANSGENE BIOTEK LTD. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRANSGENE BIOTEK LTD. stock shows the neutral signal. See more of TRANSGENE BIOTEK LTD. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.